Checkmate 901 News Today

Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.

Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.

Dr. Sonpavde discusses the efficacy and safety findings from this randomized, open-label trial enrolling patients with advanced or metastatic urothelial carcinoma who had not received prior systemic chemotherapy.